Research programme: cystic fibrosis mRNA repair therapy - Isogenis/VIRxSYS
Latest Information Update: 17 Feb 2011
At a glance
- Originator Intronn
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cystic fibrosis